Insider Buying: Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Buys 1,034,482 Shares of Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III bought 1,034,482 shares of the business’s stock in a transaction on Wednesday, March 26th. The stock was bought at an average price of $11.60 per share, for a total transaction of $11,999,991.20. Following the transaction, the insider now directly owns 795,411 shares of the company’s stock, valued at approximately $9,226,767.60. This represents a -432.71 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Surrozen Stock Down 3.3 %

NASDAQ:SRZN traded down $0.38 during mid-day trading on Friday, hitting $11.01. 5,246 shares of the company’s stock were exchanged, compared to its average volume of 22,355. Surrozen, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $18.17. The company has a 50 day simple moving average of $11.37 and a 200-day simple moving average of $10.94.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently modified their holdings of the business. Regents of The University of California acquired a new stake in Surrozen in the fourth quarter valued at $1,912,000. Stonepine Capital Management LLC lifted its holdings in Surrozen by 24.7% during the 4th quarter. Stonepine Capital Management LLC now owns 137,200 shares of the company’s stock worth $1,969,000 after buying an additional 27,200 shares during the period. Trustees of Columbia University in the City of New York bought a new stake in shares of Surrozen in the 4th quarter valued at about $688,000. Stempoint Capital LP increased its stake in shares of Surrozen by 91.7% in the fourth quarter. Stempoint Capital LP now owns 350,573 shares of the company’s stock valued at $5,031,000 after buying an additional 167,655 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Surrozen by 26.1% during the fourth quarter. Geode Capital Management LLC now owns 22,391 shares of the company’s stock worth $321,000 after acquiring an additional 4,630 shares during the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on SRZN. Guggenheim upgraded Surrozen from a “neutral” rating to a “buy” rating and set a $45.00 price target for the company in a research note on Friday, January 3rd. HC Wainwright initiated coverage on Surrozen in a report on Thursday, January 30th. They issued a “buy” rating and a $32.00 target price for the company.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.